|
1
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
European Association For The Study Of The
Liver and European Organisation For Research And Treatment Of
Cancer: EASL-EORTC clinical practice guidelines: Management of
hepatocellular carcinoma. J Hepatol 56: 908-943, 2012.
|
|
3
|
Pollutri D, Gramantieri L, Bolondi L and
Fornari F: TP53/MicroRNA interplay in hepatocellular carcinoma. Int
J Mol Sci. 17(12)2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Bruix J, Takayama T, Mazzaferro V, Chau
GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, et al: Adjuvant
sorafenib for hepatocellular carcinoma after resection or ablation
(STORM): A phase 3, randomised, double-blind, placebo-controlled
trial. Lancet Oncol. 16:1344–1354. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Akhade VS, Pal D and Kanduri C: Long
noncoding RNA: Genome organization and mechanism of action. Adv Exp
Med Biol. 1008:47–74. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Carpenter S and Fitzgerald KA: Cytokines
and long noncoding RNAs. Cold Spring Harb Perspect Biol.
10(a028589)2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Kwok ZH and Tay Y: Long noncoding RNAs:
Lincs between human health and disease. Biochem Soc Trans.
45:805–812. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bhan A, Soleimani M and Mandal SS: Long
noncoding RNA and cancer: A new paradigm. Cancer Res. 77:3965–3981.
2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Wu X, Tudoran OM, Calin GA and Ivan M: The
many faces of long noncoding RNAs in cancer. Antioxid Redox Signal.
20:922–935. 2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Cheetham SW, Gruhl F, Mattick JS and
Dinger ME: Long noncoding RNAs and the genetics of cancer. Br J
Cancer. 108:2419–2425. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Falcon T, Freitas M, Mello AC, Coutinho L,
Alvares-da-Silva MR and Matte U: Analysis of the cancer genome
atlas data reveals novel putative ncRNAs targets in hepatocellular
carcinoma. Biomed Res Int. 26(2864120)2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Xie Z, Zhou F, Yang Y, Li L, Lei Y, Lin X,
Li H, Pan X, Chen J, Wang G, et al: Lnc-PCDH9-13:1 is a
hypersensitive and specific biomarker for early hepatocellular
carcinoma. EBioMedicine. 33:57–67. 2018.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Shen W, Yuan Y, Zhao M, Li J, Xu J, Lou G,
Zheng J, Bu S, Guo J and Xi Y: Novel long non-coding RNA GACAT3
promotes gastric cancer cell proliferation through the IL-6/STAT3
signaling pathway. Tumour Biol. 37:14895–14902. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Feng L, Zhu Y, Zhang Y and Rao M: LncRNA
GACAT3 promotes gastric cancer progression by negatively regulating
miR-497 expression. Biomed Pharmacother. 97:136–142.
2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
National Health and Family Planning
Commission of the People's Republic of China: Diagnosis, treatment
and treatment of hepatocellular carcinoma (V2017). J Clin Hepatol
33: 114-126, 2017.
|
|
16
|
Xu C, Shao Y, Xia T, Yang Y, Dai J, Luo L,
Zhang X, Sun W, Song H, Xiao B and Guo J: lncRNA-AC130710 targeting
by miR-129-5p is upregulated in gastric cancer and associates with
poor prognosis. Tumour Biol. 35:9701–9706. 2014.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Gui Y and Zheng XL: Epidermal growth
factor induction of phenotype-dependent cell cycle arrest in
vascular smooth muscle cells is through the mitogen-activated
protein kinase pathway. J Biol Chem. 278:53017–53025.
2003.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Yang G, Lu X and Yuan L: LncRNA: A link
between RNA and cancer. Biochim Biophys Acta. 1839:1097–1109.
2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wang F, Ying HQ, He BS, Pan YQ, Deng QW,
Sun HL, Chen J, Liu X and Wang SK: Upregulated lncRNA-UCA1
contributes to progression of hepatocellular carcinoma through
inhibition of miR-216b and activation of FGFR1/ERK signaling
pathway. Oncotarget. 6:7899–7917. 2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sui J, Yang X, Qi W, Guo K, Gao Z, Wang L
and Sun D: Long non-coding RNA linc-USP16 functions as a tumour
suppressor in hepatocellular carcinoma by regulating PTEN
expression. Cell Physiol Biochem. 44:1188–1198. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Panzitt K, Tschernatsch MM, Guelly C,
Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder
R, Trauner M and Zatloukal K: Characterization of HULC, a novel
gene with striking up-regulation in hepatocellular carcinoma, as
noncoding RNA. Gastroenterology. 132:330–342. 2007.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhong H, Yang J, Zhang B, Wang X, Pei L,
Zhang L, Lin Z, Wang Y and Wang C: LncRNA GACAT3 predicts poor
prognosis and promotes cell proliferation in breast cancer through
regulation of miR-497/CCND2. Cancer Biomark. 22:787–797.
2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Zhou W, Wang L, Miao Y and Xing R: Novel
long noncoding RNA GACAT3 promotes colorectal cancer cell
proliferation, invasion, and migration through miR-149. Onco
Targets Ther. 11:1543–1552. 2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Yang X, Zhang W, Cheng SQ and Yang RL:
High expression of lncRNA GACAT3 inhibits invasion and metastasis
of non-small cell lung cancer to enhance the effect of
radiotherapy. Eur Rev Med Pharmacol Sci. 22:1315–1322.
2018.PubMed/NCBI View Article : Google Scholar
|
